MedTrace Logo

Neurovascular Effects of Empagliflozin

NCT07799441 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-09-02

No results posted yet for this study

Summary

The goal of this clinical trial is to examine whether empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, improves vascular and autonomic function in adults with prehypertension. The main questions this clinical trial aims to answer are:

1. Does empagliflozin improve endothelial function?
2. Does empagliflozin improve sympathetic nervous system function?

This clinical trial employs a double-blind, placebo-controlled crossover study lasting up to 6 weeks for participants with prehypertension and up to 2 weeks for normotensive participants. Participants with prehypertension will take empagliflozin or placebo for 2 weeks, separated by a 2-week washout. Normotensive participants will complete baseline, pre-treatment visits only and will serve as a control group.

Conditions

  • Blood Pressure
  • Endothelial Dysfunction

Interventions

DRUG

Empagliflozin (EMPA)

Oral ingestion for 2 weeks

OTHER

Placebo

Oral placebo for 2 weeks.

Sponsors & Collaborators

  • Kanokwan Bunsawat

    lead OTHER

Principal Investigators

  • Kanokwan Bunsawat, PHD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-09-30
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07799441 on ClinicalTrials.gov